. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedClinical Trials, Phase III as TopicDrug Administration ScheduleEtanerceptHumansImmunoglobulin G/administration & dosageImmunoglobulin G/pharmacologyImmunoglobulin G/therapeutic useInterleukin-12/antagonists & inhibitorsInterleukin-23/antagonists & inhibitorsPsoriasis/drug therapyPsoriasis/immunologyReceptors, Tumor Necrosis Factor/administration & dosageReceptors, Tumor Necrosis Factor/therapeutic useSeverity of Illness IndexUstekinumab
Substances: See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunoglobulin GInterleukin-23Receptors, Tumor Necrosis FactorInterleukin-12UstekinumabEtanercept
Year: 2008 PMID: 18974743 DOI: 10.1038/nrd2753
Source DB: PubMed Journal: Nat Rev Drug Discov ISSN: 1474-1776 Impact factor: 84.694